Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.

[1]  P. Wen,et al.  Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[3]  W. Yung,et al.  Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. , 1999, Cancer research.

[4]  S. Macdonald-Goodfellow,et al.  Hypoxia‐mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression , 1999, International journal of cancer.

[5]  T. Tlsty,et al.  A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death. , 1998, Cancer research.

[6]  N. de Tribolet,et al.  Malignant glioma: should chemotherapy be overthrown by experimental treatments? , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[8]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[9]  C. Gladson.  Expression of Integrin avß3 in Small Blood Vessels of Glioblastoma Tumors , 1996 .

[10]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[11]  W. Cavenee,et al.  Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Nose,et al.  Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. , 1996, Cancer research.

[13]  A. Ullrich,et al.  Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. , 1996, Cancer research.

[14]  D. Hanahan,et al.  Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Wilks,et al.  Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. , 1996, Cancer research.

[16]  T. Shono,et al.  Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. , 1995, Cancer research.

[17]  J. Wilcox,et al.  Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. , 1995, Journal of cell science.

[18]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[19]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[20]  P. Stewart,et al.  Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. , 1987, Journal of neurosurgery.

[21]  I. Feigin,et al.  The endothelial hyperplasia of the cerebral blood vessels with brain tumors, and its sarcomatous transformation , 1958, Cancer.

[22]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[23]  W. Reinhold,et al.  Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. , 1993, The Journal of clinical investigation.